The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.
The partners will collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.